Adverum Biotechnologies Announces Upcoming Data Presentation at The Retina Society Annual Meeting
28 October 2022 - 7:05AM
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage
company that aims to establish gene therapy as a new standard of
care for highly prevalent ocular diseases, today announced that new
data from the OPTIC trial of ixoberogene soroparvovec (Ixo-vec,
formerly referred to as ADVM-022) in wet age-related macular
degeneration (wet AMD) will be presented next week at The Retina
Society Annual Meeting in Pasadena, California. End of study,
two-year results across all four cohorts will be presented for the
first time.
Oral Presentation Title: ADVM-022 Intravitreal
Gene Therapy for Neovascular Age-Related Macular Degeneration: End
of Study Results from the 2-Year OPTIC
TrialSession: Age-Related Macular Degeneration
IIDate & Time: November 4, 2022, 9:08 AM –
9:14 AM PSTPresenter: Carl Regillo, M.D.,
F.A.C.S., chief of retina services at Wills Eye Hospital
Adverum intends to issue a press release concurrent with the
presentation and to post the data presented on the Publications
page in the Pipeline section of the company’s website.
About Wet Age-Related Macular Degeneration
Wet AMD, also known as neovascular AMD or nAMD, is an advanced
form of AMD, affecting approximately 10% of patients living with
AMD. Wet AMD is a leading cause of blindness in patients over 65
years of age, with a prevalence of approximately 20 million
individuals worldwide living with this condition. The incidence of
new cases of wet AMD is expected to grow significantly worldwide as
populations age. AMD is projected to impact 288 million people
worldwide by 2040, with wet AMD accounting for approximately 10% of
those cases.
About OPTIC Trial of ADVM-022 in Wet AMD
ADVM-022, ixoberogene soroparvovec (Ixo-vec), is Adverum’s
clinical-stage gene therapy product candidate being developed for
the treatment of wet AMD. ADVM-022 (Ixo-vec) utilizes a propriety
vector capsid, AAV.7m8, carrying an aflibercept coding sequence
under the control of a proprietary expression cassette. Unlike
other ophthalmic gene therapies that require a surgery to
administer the gene therapy under the retina (sub-retinal approach)
ADVM-022 has the advantage of being administered as a one-time IVT
injection in the office and is designed to deliver long-term
efficacy and reduce the burden of frequent anti-VEGF injections,
optimize patient compliance, and improve vision outcomes for
patients with wet AMD.
The OPTIC trial is designed as a multi-center, open-label,
dose-ranging, safety, and efficacy trial of ADVM-022 (Ixo-vec) in
participants with wet AMD who have demonstrated responsiveness to
anti-VEGF treatment. Patients in OPTIC are treatment-experienced,
and previously required frequent anti-VEGF injections to manage
their wet AMD and to maintain functional vision.
About Adverum Biotechnologies
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage
company that aims to establish gene therapy as a new standard of
care for highly prevalent ocular diseases with the aspiration of
developing functional cures to restore vision and prevent
blindness. Leveraging the research capabilities of its proprietary,
intravitreal (IVT) platform, Adverum is developing durable,
single-administration therapies, designed to be delivered in
physicians’ offices, to eliminate the need for frequent ocular
injections to treat these diseases. Adverum is evaluating its novel
gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly
referred to as ADVM-022), as a one-time, IVT injection for patients
with neovascular or wet age-related macular degeneration. By
overcoming the challenges associated with current treatment
paradigms for these debilitating ocular diseases, Adverum aspires
to transform the standard of care, preserve vision, and create a
profound societal impact around the globe. For more information,
please visit www.adverum.com.
Corporate & Investor Inquiries
Anand ReddiVice President, Head of Corporate Strategy, External
Affairs and EngagementAdverum Biotechnologies, Inc.T:
650-649-1358E: areddi@adverum.com
Media
Megan TalonAssociate Director, Corporate CommunicationsAdverum
Biotechnologies, Inc.T: 650-649-1006E: mtalon@adverum.com
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Apr 2023 to Apr 2024